【摘要】 目的:比较国产和进口培美曲塞分别联合卡铂方案对非小细胞肺癌的疗效和药物经济学评价。方法:提取2015-2018年广西壮族自治区人民医院确诊为非小细胞肺癌Ⅲ～Ⅳ期并使用培美曲塞联合卡铂方案化疗的患者84例进行回顾性分析,其中国产组46例和进口组36例,统计2组间的RR、DCR、不良反应发生率和患者的住院总费用,分别计算成本效果比和增量成本效果比。结果:国产组有效率为6.5%,显著低于进口组的33.3%,P<0.05,国产组、进口组的疾病控制率为89.1%,88.9%,差异无显著性;国产组3～4级不良反应发生率(6.4%,3.5%)显著高于进口组(0%),P<0.05;1～2级不良反应如白细胞减少、胃肠道反应、轻度肝酶升高的发生率稍高于进口组,但差异无显著性。E-ERR分析中国产组、进口组C/E分别为1 125 172元和608 228元,ΔC/ΔE为482 368元;E-EDCR分析中国产组、进口组C/E分别为82 228元和227 829元,ΔC/ΔE为-6 463 736元;结论:进口培美曲塞临床治愈率高,平均治疗成本和增量成本低,不良反应发生率小,更具有药物经济学优势。更多还原

【Abstract】 OBJECTIVE To compare the efficacy and pharmacoeconomic evaluation of domestic and imported pemetrexed combined with carboplatin regimen in NSCLC.METHODS A retrospective analysis of 84 patients with stageⅢ-Ⅳ NSCLCdiagnosed in the People’s Hospital of Guangxi Zhuang Autonomous Region from 2015 to 2018 and treated with pemetrexed pluscarboplatin regimen was performed.Among them,46 patients in the domestic group and 36 patients in the imported groupwere included.The RR,DCR,incidence of adverse reactions,and total hospitalization costs as well as the cost-effectivenessratio and incremental cost-effectiveness ratio were calculated.RESULTS The effective rate of the domestic group was 6.5%,which was significantly lower than 33.3%of the import group(33.3%,P<0.05).The disease control rates in the domesticand imported groups were 89.1%and 88.9%,respectively.There was no significant difference between the two groups.Theincidence of grade 3-4 adverse reactions(6.4%,3.5%)in the domestic group was significantly higher than that in the importgroup(0%,P<0.05).The incidence of grade 1-2 adverse reactions such as leukopenia,gastrointestinal reaction and mildhepatase was slightly higher than that of the import group,but no significant difference was observed between these twogroups.E-ERR analysis showed that the C/E of domestic group and imported group were 1 125 172 yuan and 608 228 yuan re-spectively withΔC/ΔE being 482 368 yuan;E-EDCR analysis showed that the C/E of domestic and import group were 82 228 yuan and 227 829 yuan respectively withΔC/ΔE being-6 463 736 yuan.CONCLUSION Imported peimecloxacil has exhibiteda higher clinical cure rate,lower average treatment cost and incremental cost,low incidence of adverse reactions with more advantages of pharmacoeconomics.更多还原